Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

OptimizeRx Corp Director's Dealing 2022

Jan 11, 2022

33090_dirs_2022-01-11_3f5a24ad-efbe-40fd-8b94-22c5229cd8e6.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OptimizeRx Corp (OPRX)
CIK: 0001448431
Period of Report: 2022-01-07

Reporting Person: FEBBO WILLIAM J (Director, CHIEF EXECUTIVE OFFICER)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-01-07 Common Stock F 9627 Acquired 479004 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2022-01-07 Unvested Restricted Stock Award $ F 9627 Disposed 2024-01-07 Common Stock (28883) Direct

Footnotes

F1: The Reporting Person acquired these shares pursuant to a Restricted Stock Award. The award vests 1/3 at the end of each anniversary from issuance.